Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. The companys lead development program, CO-sTiRNA, is a novel targeted immuno-oncology gene therapy for the treatment of multiple cancers. Its second lead development program, MRI-1867, is a peripherally restricted dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS. Strategic partners of Scopus BioPharma include City of Hope, the National Institutes of Health, and Hebrew University, including their respective scientists, medical doctors, and other senior researchers.